Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

PSMA MRI guidad prostata SBRT (ARGOS)/omfattande, longitudinell utvärdering av avbildningsbiomarkörer efter strålbehandling (CLIMBER) (ARGOS/CLIMBER)

PSMA MRI guidad prostata SBRT(ARGOS)/omfattande, longitudinell utvärdering av avbildningsbiomarkörer efter strålbehandling (CLIMBER)

This study is a prospective Phase I/II protocol enrolling men with either high intermediate-risk or high-risk or very high-risk prostate cancer. All men will have PSMA Targeted PET (using the PSMA targeting ligand PSMA 1007) and multiparametric magnetic resonance imaging (mpMRI) for delineation of intra-prostatic foci of cancer and any involved regional lymph nodes based on high SUV uptake on PET or mpMRI (T2W, DWI/ADC, DCE) appearance suspicious for cancer. Tumour delineation will be performed by fusing the PSMA PET and mpMRI with planning CT simulation images. Fiducial marker implantation for treatment guidance will be mandatory but use of other organs at risk protection strategies (i.e. GU Loc, Space-OAR) will be allowed but not mandatory. Patients will be treated with image-guided SBRT using the fiducial markers for intra-fraction motion management. Dose escalation to imaging defined targets (intra-prostatic and involved nodes on PSMA PET + MRI) will be accomplished through a simultaneous boost technique. Maintaining dose to organs at risk will take precedence over boost dose targets (targeted maximum dose of 50Gy/5 fractions to imaging defined prostatic lesion; 35Gy/5 fractions to imaging defined involved nodes).

Cohort extension: We hypothesize that integration of neoadjuvant androgen deprivation therapy will provide for pretreatment cancer downstaging and will allow us to achieve higher target doses to the imaging defined DILs than currently achieve. Additionally, we plan to include a novel sodium MRI protocol into the baseline imaging to compare DIL volumes delineated by this modality to those by mpMRI and PSMA PET and to characterize changes in sodium MRI in response to ADT alone and subsequent radiotherapy

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

50

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Ontario
      • London, Ontario, Kanada, N6A 5W9
        • London Health Sciences Centre
      • Toronto, Ontario, Kanada, M4N3M5
        • Sunnybrook Research Institute

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Manlig

Beskrivning

Inclusion Criteria:

  • Age > 18 years of age
  • Histologically confirmed carcinoma of the prostate
  • High-intermediate risk or high risk as defined by NCCN criteria:
  • High intermediate: 2 or 4 intermediate risk factors (T2B-T2C, Gleason GG 2 or 3, PSA 10-20) or GG 3 or intermediate risk with equal or >50% biopsy core involvement
  • High-risk: one of T3a, Gleason GG 4 or 5, or PSA >20 ng/ml
  • Very-high risk: one of primary Gleason Pattern 5, >4 cores Grade Group 4 or 5, clinical T3b, or more than 1 high-risk feature
  • Conventional imaging (bone scan and abdominal pelvic computed tomography) negative for extra-pelvic nodal, skeletal or visceral metastases
  • Willing to give informed consent to participate in this clinical trial
  • Able and willing to complete EPIC questionnaires

Exclusion Criteria:

  • Prior prostate cancer treatment (apart from prior 5-alpha reductase inhibitor treatment); androgen deprivation therapy prior to enrollment or treatment planning not permitted
  • Men with clinical T4 disease are excluded
  • Contraindication to radical prostate radiotherapy e.g. connective tissue disease or inflammatory bowel disease
  • Contraindication to prostate MRI (i.e. non0compatible stent, pacemaker, prosthesis, etc.)
  • Contraindication to use of PSMA PET agent PSMA 1007 due to intolerance or allergy
  • Anticoagulation medication (if unsafe to discontinue for gold seed insertion)
  • Diagnosis of bleeding diathesis
  • Poor baseline urinary function defined as a score of 5 ("big problem") on question 5 of the EPIC 26 (Overall, how big a problem has your urinary function been for you during the last 4 weeks?)
  • Definitive extra-pelvic nodal or distant metastatic disease on conventional staging investigations

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Men with high intermediate to very high risk prostate cancer

Men with high intermediate to very high risk prostate cancer

Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Six months of androgen deprivation therapy will commence with the end of radiotherapy (concurrent plus adjuvant)

Patients will receive 35Gy/5 fractions to the whole prostate (25Gy to whole Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Pelvic lymph nodes will receive 25Gy/5 fractions synchronous with prostate treatment with a simultaneous boost to imaging involved nodes to a maximum of 35Gy/5 fractions. Eighteen months of androgen deprivation therapy will commence with the end of radiotherapy (concurrent plus adjuvant)

Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Androgen deprivation therapy will commence 3 months before radiotherapy (concurrent plus adjuvant) and will continue for a total of 6 months.

Patients will receive 35Gy/5 fractions to the whole prostate (25 Gy to proximal Seminal Vesicles) with a simultaneous boost to PET/MRI defined intra-prostatic foci to a target maximum dose of 50Gy/5 fractions. Androgen deprivation therapy will commence 3 months before radiotherapy (concurrent plus adjuvant) and will continue for a total of 18 months.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
6-month Toxicity
Tidsram: 6-months

6-month gastrointestinal (GI) and genitourinary (GU) toxicity using the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).

6-months
6-week Toxicity
Tidsram: 6-weeks

6-week gastrointestinal (GI) and genitourinary (GU) toxicity using the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).

6-weeks
Expansion cohort: Median minimum dose to dominant intra-prostatic lesion
Tidsram: 6-months

Expansion cohort: Median minimum dose to dominant intra-prostatic lesion

6-months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Quality of Life measured by the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaires
Tidsram: 5 years

Quality of life measured by the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaires.

5 years
Disease Free Survival
Tidsram: 5 years

Five-year disease-free survival (DFS) as a composite of biochemical control, patient death or development of clinical metastases or institution of salvage ADT.

5 years

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Translational Endpoint 1
Tidsram: 24 months

Serial PSMA PET/MRI images will be collected at baseline, 6 months and 2 years to characterize the imaging response of prostate cancer to treatment and potentially identify imaging biomarkers (including pharmacokinetic, radiomic and quantitative PET and mpMRI metrics) that predict for five-year DFS

24 months
Translational Endpoint 2
Tidsram: 24 Months

Baseline collection of diagnostic tissue biopsy samples and serial collection of blood and urine over multiple time points (baseline, 6 months, 1 year, 2 years post radiotherapy) for correlative biologic biomarker analyses with imaging changes and disease-free survival and toxicity post treatment

24 Months
Translational Endpoint 3
Tidsram: 2 years

A prostate biopsy at baseline and 2 years will allow for correlation of histopathology with PSMA PET/MRI images. Specifically, we will investigate biopsy correlations with pre-treatment PSMA PET/MRI images and whether a negative PSMA PET/MRI is correlated with a negative 2-year post treatment biopsy (shown to correlate with long term disease control

2 years
Translational Endpoint 4
Tidsram: 5 years

Examine novel clinical prognostic biomarkers (i.e. percentage of Gleason Pattern 4 on biopsy, 4- year PSA response rate) and their correlation with imaging findings and 5-year Disease Free Survival

5 years
Translational Endpoint- Expansion cohort
Tidsram: 6 months

Characterize intra-prostatic foci on pre, post 3-month ADT and 6 months post radiotherapy on PSMA PET/MRI + sodium MRI imaging

6 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 maj 2022

Primärt slutförande (Beräknad)

15 december 2028

Avslutad studie (Beräknad)

15 december 2028

Studieregistreringsdatum

Först inskickad

12 januari 2022

Först inskickad som uppfyllde QC-kriterierna

25 februari 2022

Första postat (Faktisk)

8 mars 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera